Hepatitis b drug combo shows promise but study halted early
NCT ID NCT02738008
First seen Jan 15, 2026 · Last updated May 08, 2026 · Updated 15 times
Summary
This study looked at adding an experimental drug called ARC-520 to standard hepatitis B treatments (entecavir or tenofovir) in 12 people with chronic hepatitis B. Participants received 9 doses of ARC-520 over 36 weeks. The goal was to see if the combination could reduce a key virus marker (HBsAg) by at least 90%. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
Hong Kong, 999077, China
-
Research Site 2
Leipzig, 04103, Germany
-
Research Site 3
Busan, 602-739, South Korea
-
Research Site 4
Seoul, 110-744, South Korea
-
Research Site 5
Incheon, 405-760, South Korea
-
Research Site 6
Seoul, 120-752, South Korea
Conditions
Explore the condition pages connected to this study.